Comparing the current results to its competitors, Ligand Pharmaceuticals Incorporated reported Revenue increase in the 2 quarter 2026 by 33.73 % year on year. The sales growth was above Ligand Pharmaceuticals Incorporated's competitors' average revenue growth of 5.86 %, achieved in the same quarter.
Ligand Pharmaceuticals Incorporated Net Income in the 2 quarter 2026 grew year on year by 900.78%, while most of its competitors have experienced a contraction in net income by -59.68 %.
Ligand Pharmaceuticals Incorporated's Comment on Competition and Industry Peers
The company faces competition in its Captisol business from other suppliers of cyclodextrin excipients and alternative technologies designed to enhance the solubility or stability of active pharmaceutical ingredients (APIs). Some drugs developed by the company, its licensees, and partners may compete with existing therapies or drugs under development by other companies. Academic institutions, government agencies, and other public and private organizations conducting research may also seek patent protection for potentially competing products or technologies and may collaborate with competitors. The company's competitive position relies on its ability to secure patent protection and develop proprietary products or processes. The company has ongoing minimum purchase commitments under its agreement with Hovione.
September 7, 2024
In the ever-evolving landscape of biotechnology and pharmaceuticals, the ability to innovate and provide solutions that address unmet medical needs is paramount. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has achieved a significant milestone in this regard, as its partner Travere Therapeutics, Inc. (NASDAQ: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI (sparsentan). This breakthrough therapy stands out as the only non-immunosuppressive treatment shown to significantly slow kidney function decline in adults suffering from primary IgA Nephropathy (IgAN), a chronic disease that poses a substantial risk for progressive kidney damage.The approval, celebrate...
June 18, 2024
In a significant leap forward for public health, Ligand Pharmaceuticals Incorporated recently announced that its pharmaceutical collaborator Merck has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine. Known within the scientific community as V116 during its development phase, this vaccine has been greenlit for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults a crucial milestone given the high morbidity and mortality associated with these conditions.Pneumococcal diseases, caused by the bacterium Streptococcus pneumoniae, are insidious health threats that result in severe infections such as bacteremi...
Publicly Traded Peers of Ligand Pharmaceuticals Incorporated
Legend Biotech Corporation Share Performance
-40.35%
One Year
Legend Biotech Corporation
Profile
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Ligand Pharmaceuticals Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ligand Pharmaceuticals Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
